Antineoplastics
Conditions
Interventions
Experimental and control group: This is an evaluative, randomized, three-arm, double-blind, placebo-controlled study. All patients are volunteers at the Hospital Regional do Câncer de Passos, located
D12.125.095.226
Sponsors
Universidade Federal de Alfenas
Universidade Federal de Alfenas
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients aged 18 years or older; with a diagnosis of gastrointestinal cancer confirmed by biopsy and histological analysis; first neoplasm; under treatment for a maximum of 12 months; capable of supplementation by oral administration
Exclusion criteria
Exclusion criteria: Patients who had any chronic or acute condition that limited their ability to participate in the study; the inability to swallow; and refusal to sign the informed consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the potential of L-citrulline for mitigating the side effects of toxicity caused by chemotherapy treatment, after supplementation for 28 days, based on the comparison of biochemical tests performed at the beginning and end of supplementation. We also want to find differences between the intervention groups and the placebo control group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the potential of L-citrulline on the mitigation of renal and hepatic toxicity through supplementation in dosages developed for this purpose compared to the beginning. It is also desired to find differences between the intervention groups with the placebo control. | — |
Countries
Brazil
Contacts
Public ContactRoberta Ribeiro Cruz
Universidade Federal de Alfenas
Outcome results
None listed